Year All20242023202220212020201920182017201620152014 Jan 24, 2024 Soleno Therapeutics Strengthens Leadership Team with Key Appointments Jan 05, 2024 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 10, 2023 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 07, 2023 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results Nov 06, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome Oct 04, 2023 Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium Oct 04, 2023 Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium Oct 02, 2023 Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares Sep 28, 2023 Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants Sep 27, 2023 Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
Nov 07, 2023 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 06, 2023 Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
Oct 04, 2023 Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
Oct 04, 2023 Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
Oct 02, 2023 Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 28, 2023 Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
Sep 27, 2023 Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants